{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021281","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.882382+00:00","generated_at":"2026-06-15T03:55:59.953258+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biodesix Q1 revenue $9.1M (+38% YoY); core lung diagnostics up 86% to $8.6M","bullets":["Total revenue $9.1M, +38% YoY; core lung diagnostic revenue $8.6M, +86% YoY.","Net loss $18.7M ($0.24 per share); operating expenses $22.3M up 25% YoY.","Gross margin improved to 65% from 51% due to shift from lower-margin COVID-19 tests.","COVID-19 testing revenue down 99% YoY; company discontinues commercial COVID-19 testing.","Reaffirmed 2023 total revenue guidance $52M-$55M; cash $25.3M as of March 31."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021281","json":"https://secwatch.observer/filing/0000950170-23-021281.json","markdown":"https://secwatch.observer/filing/0000950170-23-021281.md","text":"https://secwatch.observer/filing/0000950170-23-021281.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000095017023021281/0000950170-23-021281-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000095017023021281/bdsx-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:55:59.953258+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e291c2330b56e61f3c7eaf5a55dd131fae91feb","claim":"BIODESIX INC reported the first quarter ended March 31, 2023 results: revenue $9.1 million, net income $18.7 million, EPS $0.24. Guidance reaffirmed.","evidence_excerpt":"First Quarter 2023 Financial Results For the three-month period ended March 31, 2023, as compared to the same period of 2022 (where applicable): • Total revenue of $9.1 million, an increase of 38%, driven primarily by strong year-over-year growth in core lung diagnostics: o Core lung diagnostic revenue of $8.6 million reflected a year-over-year increase of 86% driven primarily by the continued adoption of Nodify Lung® nodule management tests; o BioPharma Services revenue of $0.4 million decreased 55% year-over-year. Timelines for existing and new agreements continue to be impacted by delayed enrollment in clinical trials; entered the second quarter of 2023 with continued strong dollars under contract; o COVID-19 testing revenue decreased by 99% year-over-year, and consistent with our revenue guidance. In connection with the expected expiration of the Public Health Emergency declaration, the Company will no longer provide COVID-19 diagnostic testing services commercially; • First quarte","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439725/000095017023021281/0000950170-23-021281-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$9.1 million"},{"label":"Net income","value":"$18.7 million"},{"label":"EPS","value":"$0.24"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}